- Home
- GPCR
GPCR
Structure Therapeutics Inc.
as 03-31-2025 4:00pm EST
Stocks
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | $80.71 | AVG Volume (30 days): | 712.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.24 - $62.74 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Structure Therapeutics Inc. News
GPCR Breaking Stock News: Dive into GPCR Ticker-Specific Updates for Smart Investing
Investor's Business Daily
a month ago
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
MT Newswires
a month ago
William Blair Initiates Structure Therapeutics at Outperform
GlobeNewswire
a month ago
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
Motley Fool
a month ago
Why Structure Therapeutics Stock Was Stumbling This Week
GlobeNewswire
2 months ago
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
Simply Wall St.
2 months ago
We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate
Barrons.com
3 months ago
Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.
GlobeNewswire
3 months ago
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Compare GPCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GPCR Structure Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.